Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Hybrid compton-PET imaging for ion-range verification: a preclinical study for proton, helium, and carbon therapy at HIT

  • Balibrea-Correa, Javier
  • Lerendegui-Marco, Jorge
  • Ladarescu, Ion
  • Guerrero, Carlos
  • Rodríguez-González, Teresa
  • Jiménez-Ramos, Maria del Carmen
  • Quesada, Jose Manuel
  • Bauer, Julia
  • Brons, Stephan
  • Domingo-Pardo, César
  • Morell-Ortega, Sergio|||0009-0001-7639-2915
[EN] Enhanced-accuracy ion-range verification in real time shall enable a significant step forward in the use of therapeutic ion beams. Positron-emission tomography (PET) and prompt-gamma imaging (PGI) are two of the most promising and researched methodologies, both of them with their own advantages and challenges. Thus far, both of them have been explored for ion-range verification in an independent way. However, the simultaneous combination of PET and PGI within the same imaging framework may open-up the possibility to exploit more efficiently all radiative emissions excited in the tissue by the ion beam. Here, we report on the first preclinical implementation of an hybrid PET-PGI imaging system, hereby exploring its performance over several ion beam species (H, He and C), energies (55¿275 MeV) and intensities ( - ions/spot), which are representative of clinical conditions. The measurements were carried out using the pencil-beam scanning technique at the synchrotron accelerator of the heavy ion therapy center in Heidelberg utilizing an array of four Compton cameras in a twofold front-to-front configuration. The results demonstrate that the hybrid PET-PGI technique can be well suited for relatively low energies (55¿155 MeV) and beams of protons. On the other hand, for heavier beams of helium and carbon ions at higher energies (155¿275 MeV), range monitoring becomes more challenging owing to large backgrounds from additional nuclear processes. The experimental results are well understood on the basis of realistic Monte Carlo calculations, which show a satisfactory agreement with the measured data. This work can guide further upgrades of the hybrid PET-PGI system toward a clinical implementation of this innovative technique., This work derives from fundamental research carried out with funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation program (ERC Consolidator Grant project HYMNS, with grant agreement No. 681740) and part of this work has been funded under ERC Proof-of-Concept Grant GNVISION (Grant Agreement 101113330). The authors acknowledge support from the Spanish Ministerio de Ciencia e Innovación under grants PDC2021-121536-C21, PID2019-104714GB-C21 and RTI2018-098117-B-C21. We acknowledge support from the Severo Ochoa Grant CEX2023-001292-S funded by MCIU/AEI. T. Rodriguez-Gonzalez acknowledges the Spanish FPI predoctoral grant. J. Balibrea-Correa is supported by grant ICJ220-045122-I and J. Lerendegui-Marco is supported by grant FJC2020-044688-I funded by MCIN/AEI/10.13039/501100011033 and CIAPOS/2022/020 funded by MICIN/AEI and Generalitat Valenciana. Ion Ladarescu was funded by the R&D grant PDC2022-133382-I00, funded by the Spanish Ministry of Science (MCIN/AEI/10.13039/501100011033). M.C. Jiménez-Ramos acknowledges the support to this work through a VI PPIT-US contract. We would like to thank the crew at the Electronics Laboratory of IFIC, in particular Manuel Lopez Redondo and Jorge Nácher Arándiga for their excellent and efficient work prototyping and manufacturing customized PCBs for this work.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characterization of a novel proton-CT scanner based on Silicon and LaBr3(Ce) detectors

  • Nácher, Enrique
  • Briz, José Antonio
  • Nerio, A. N.
  • Perea, Ángel
  • García Távora, Vicente
  • Tengblad, Olof
  • Ciemala, M.
  • Cieplicka-Orynczak, N.
  • Maj, A.
  • Mazurek, K.
  • Olko, P.
  • Zieblinski, M.
  • García Borge, María José
9 pags., 8 figs., 1 tab., Treatment planning systems at proton-therapy centres entirely use X-ray computed tomography (CT) as primary imaging technique to infer the proton treatment doses to tumour and healthy tissues. However, proton stopping powers in the body, as derived from X-ray images, suffer from important proton-range uncertainties. In order to reduce this uncertainty in range, one could use proton-CT images instead. The main goal of this work is to test the capabilities of a newly-developed proton-CT scanner, based on the use of a set of tracking detectors and a high energy resolution scintillator for the residual energy of the protons. Different custom-made phantoms were positioned at the field of view of the scanner and were irradiated with protons at the CCB proton-therapy center in Krakow. We measured with the phantoms at different angles and produced sinograms that were used to obtain reconstructed images by Filtered Back-Projection. The obtained images were used to determine the capabilities of our scanner in terms of spatial resolution and proton Relative Stopping Power (RSP) mapping and validate its use as proton-CT scanner. The results show that the scanner can produce medium-high quality images, with spatial resolution better than 2 mm in radiography, below 3 mm in tomography and resolving power in the RSP comparable to other state-of-the-art pCT scanners., This work has been mainly supported by the PRONTO-CM and ASAP-CM projects (Grants B2017/BMD-3888 and P2022/BMD-7434 from Comunidad de Madrid, Spain) that has sponsored J.A. Briz and A.N. Nerio. The experiments have been carried out with the support of the European Union Horizon 2020 research and innovation programme under Grant Agreement No. 654002 (ENSAR2) and Grant Agreement No [730983] (INSPIRE). This publication is also part of the R&D Grants PID2022-140162NB-I00, PID2022-138297NB-C21 and PDC2022-133382-I00, funded by the Spanish Ministry of Science (MCIN/AEI/10.13039/501100011033) and Grant CIPROM/2021/064 from Generalitat Valenciana. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Iodine-substituted hydroxyapatite nanoparticles and activation of derived ceramics for range verification in proton therapy

  • Magro Hernández, R.
  • Muñoz-Noval, A.
  • Briz, José Antonio
  • Murias, J. R.
  • Espinosa-Rodríguez, A.
  • Fraile, Luis M.
  • Agulló Rueda, F.
  • Ynsa, M. D.
  • Tavares de Sousa, C.
  • Cortés-Llanos, B.
  • García-López, G.
  • Nácher, Enrique
  • García Tavora, Vicente
  • Mont I Geli, N.
  • Nerio, A.N.
  • Onecha, V. V.
  • Pallàs, M.
  • Tarifeño, A.
  • Tengblad, Olof
  • Manso Silván, M.
  • Viñals, S.
8 pages, 7 figures, 2 tables, Osteosarcoma is a radioresistant cancer, and proton therapy is a promising radiation alternative for treating cancer with the advantage of a high dose concentration in the tumor area. In this work, we propose the use of iodine-substituted hydroxyapatite (IHAP) nanomaterials to use iodine (127I) as a proton radiation tracer, providing access to range verification studies in mineralized tissues. For this purpose, the nanomaterials were synthesized at four iodine concentrations via hydrothermal synthesis. The materials were characterized via different microstructural techniques to identify an optimal high iodine concentration and pure apatite phase nanomaterial. Finally, such pure IHAP powders were shaped and irradiated with proton beams of 6 and 10 MeV, and their activation was demonstrated through subsequent decay analysis. The materials could be integrated into phantom structures for the verification of doses and ranges of protons prior to animal testing and clinical proton therapy treatments of tumors located deep under combined soft and calcified tissues., The current research was funded through grants PID2020-112770RB-C21, PDC2022-133382-I00, PID2020-112770RB-C22 and PID2023-151371OB-C22 by MCIN/AEI/10.13039/501100011033 and FEDER, EU, grant FLASHOnChip (PLEC2022-009256) by MCIN, ASAP-CM(P2022/BMD-7434) from DGI-Comunidad de Madrid and CIPROM/2021/064 from Generalitat Valenciana. Beamtime at the CMAM through experiment EUB004/22 is acknowledged., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Iodine-substituted hydroxyapatite nanoparticles and activation of derived ceramics for range verification in proton therapy

  • Magro Hernández, Raúl
  • Muñoz Noval, Alvaro
  • Briz, José Antonio
  • Rodríguez Murias, Javier
  • Espinosa Rodríguez, Andrea
  • Fraile, Luis Mario
  • Agulló Rueda, Fernando
  • Ynsa, Maria Dolores
  • Tavares de Sousa, Célia
  • Cortés Llanos, Belén
  • García López, Gastón
  • Nacher González, Enrique
  • García Távora, Vicente
  • Mont i Geli, Nil|||0000-0003-4249-7281
  • Nerio Aguirre, Amanda
  • Valladolid Onecha, Víctor
  • Pallàs i Solís, Max|||0000-0001-6137-0812
  • Tarifeño Saldivia, Ariel
  • Tengblad, Olof Erik
  • Manso Silvan, Miguel
  • Viñals Onsens, Silvia
Osteosarcoma is a radioresistant cancer, and proton therapy is a promising radiation alternative for treating cancer with the advantage of a high dose concentration in the tumor area. In this work, we propose the use of iodine-substituted hydroxyapatite (IHAP) nanomaterials to use iodine (127I) as a proton radiation tracer, providing access to range verification studies in mineralized tissues. For this purpose, the nanomaterials were synthesized at four iodine concentrations via hydrothermal synthesis. The materials were characterized via different microstructural techniques to identify an optimal high iodine concentration and pure apatite phase nanomaterial. Finally, such pure IHAP powders were shaped and irradiated with proton beams of 6 and 10 MeV, and their activation was demonstrated through subsequent decay analysis. The materials could be integrated into phantom structures for the verification of doses and ranges of protons prior to animal testing and clinical proton therapy treatments of tumors located deep under combined soft and calcified tissues., The current research was funded through grants PID2020-112770RB-C21, PDC2022-133382-I00 and PID2020-112770RB-C22 and PID2023-151371OB-C22 by MCIN/AEI/10.13039/501100011033 and FEDER, EU, grant FLASHOnChip (PLEC2022-009256) by MCIN, ASAP-CM (P2022/BMD-7434) from DGI-Comunidad de Madrid and CIPROM/2021/064 from Generalitat Valenciana. Beamtime at the CMAM through experiment EUB004/22 is acknowledged., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Iodine-substituted hydroxyapatite nanoparticles and activation of derived ceramics for range verification in proton therapy

  • Magro Hernández, Raúl
  • Muñoz Noval, Alvaro
  • Briz, José Antonio
  • Rodríguez Murias, Javier
  • Espinosa Rodríguez, Andrea
  • Fraile, Luis Mario
  • Agulló Rueda, Fernando
  • Ynsa, Maria Dolores
  • Tavares de Sousa, Célia
  • Cortés Llanos, Belén
  • García López, Gastón
  • Nacher González, Enrique
  • García Távora, Vicente
  • Mont i Geli, Nil
  • Nerio Aguirre, Amanda
  • Valladolid Onecha, Víctor
  • Pallàs i Solís, Max
  • Tarifeño Saldivia, Ariel
  • Tengblad, Olof Erik
  • Manso Silvan, Miguel
  • Viñals Onsens, Silvia
Osteosarcoma is a radioresistant cancer, and proton therapy is a promising radiation alternative for treating cancer with the advantage of a high dose concentration in the tumor area. In this work, we propose the use of iodine-substituted hydroxyapatite (IHAP) nanomaterials to use iodine (127I) as a proton radiation tracer, providing access to range verification studies in mineralized tissues. For this purpose, the nanomaterials were synthesized at four iodine concentrations via hydrothermal synthesis. The materials were characterized via different microstructural techniques to identify an optimal high iodine concentration and pure apatite phase nanomaterial. Finally, such pure IHAP powders were shaped and irradiated with proton beams of 6 and 10 MeV, and their activation was demonstrated through subsequent decay analysis. The materials could be integrated into phantom structures for the verification of doses and ranges of protons prior to animal testing and clinical proton therapy treatments of tumors located deep under combined soft and calcified tissues., The current research was funded through grants PID2020-112770RB-C21, PDC2022-133382-I00 and PID2020-112770RB-C22 and PID2023-151371OB-C22 by MCIN/AEI/10.13039/501100011033 and FEDER, EU, grant FLASHOnChip (PLEC2022-009256) by MCIN, ASAP-CM (P2022/BMD-7434) from DGI-Comunidad de Madrid and CIPROM/2021/064 from Generalitat Valenciana. Beamtime at the CMAM through experiment EUB004/22 is acknowledged., Peer Reviewed, Postprint (published version)
Docta Complutense
Publicación Contribución de congreso (ConferenceOutput)

Off-line total absorption spectroscopy of 152Tb for its medical interest

  • Nácher, Enrique
  • Fonseca, Carolina
  • Köster, Ulli
  • Briz Monago, José Antonio
  • Parra, Selene
  • Agramunt, Jorge
  • Algora, Alejandro
  • Fraile Prieto, Luis Mario
  • Gelletly, William
  • Llanos, Marcos
  • Page, Christopher
  • Rubio, Berta
  • Taín, José L.
  • Yue, Zixuan
Radionuclides are widely applied in different medical techniques for diagnosis and treatment. The efficacy of the treatments, as well as the off-target dose minimisation in both diagnosis and treatment depend, among other things, on the decay characteristics of the radionuclide in use: the different particles and radiation emitted, the emission energies and the emission probabilities. These are essential for the calculation of the dose administered to the patient or to medical personnel or caretakers in medical imaging or treatment with radionuclides. In this work we present the Total Absorption Spectroscopy of Tb-152 for its relevance in medicine and whose decay properties were not well enough established.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Time response of an undoped LaCl3 crystal

  • Caballero Rodríguez, Miriam
  • Sánchez Tembleque Verbo, Víctor
  • Fraile Prieto, Luis Mario
  • Fonseca Vargas, C.
  • Gaitán Domínguez, Sara
  • Kim, H.J.
  • Martínez Nouvilas, Víctor
  • Martínez Roig, M.
  • Nácher, E.
  • Udías Moinelo, José Manuel
  • Vuong, P.Q.
We have characterized a detector equipped with an undoped LaCl truncated cone crystal with dimensions of 22.5 mm in the largest diameter, 16 mm in the smallest diameter, and 16 mm in height, coupled to a fast Photonis XP2020/URQ photomultiplier tube (PMT). Its time response at 511 keV (22Na) and 60Co photon energies has been measured against a reference detector using a fast digitizer module by digital signal processing methods based on a genetic algorithm. The time resolution was optimized by the choice of the photomultiplier bias voltage and the fine-tuning of the digital parameters of the time pickup algorithm. The de-convoluted full width at half maximum (FWHM) time resolution is found to be 250 ± 10 ps at 60Co energies, and 444 ± 8 ps using positron annihilation -rays from 22Na, providing good prospects for the use of the crystal in applications requiring a fast time response.